X Zhang1, Z Wang, Y Kang, X Li, X Ma, L Ma. 1. Department of Respiratory and Critical Care Medicine, People's Hospital of Zhengzhou University, Weiwu Road 7, Zhengzhou, Henan, China.
Abstract
BACKGROUND: MCAM has been recently identified as a biomarker for epithelial-mesenchymal transition (EMT) and is potentially involved in metastasis of cancer. The current study aimed at investigating the expression of MCAM in non-small-cell lung cancer (NSCLC) and its clinico-pathological significance. METHODS: A follow-up analysis was performed on 118 patients with NSCLC resected by lobectomy or pneumectomy with systematic lymph node dissection. All patients were followed for 6-60 months. Immunostaining of tissue sections from primary tumors and their lymph node metastasis was performed and evaluated using monoclonal antibody against MCAM, E-cadherin, and vimentin. Correlations were investigated between MCAM immunostaining in primary tumors and E-cadherin, vimentin immunostaining, lymph node metastasis, and survival. RESULTS: MCAM protein expression was found in 46.61 % of squamous cell carcinomas and 37.47 % of adenocarcinomas; MCAM expression positively correlated with vimentin, but inversely with E-cadherin (both P values <0.05). There were significant correlations between the MCAM immunostaining score in primary tumors and in their lymph node metastasis (P = 0.03). According to the Kaplan-Meier survival estimate, the level of MCAM expression in primary tumors was a statistically significant prognostic factor (P < 0.05). CONCLUSIONS: MCAM expression in surgically treated NSCLC is clearly associated with lymph node metastasis and poor prognosis.
BACKGROUND:MCAM has been recently identified as a biomarker for epithelial-mesenchymal transition (EMT) and is potentially involved in metastasis of cancer. The current study aimed at investigating the expression of MCAM in non-small-cell lung cancer (NSCLC) and its clinico-pathological significance. METHODS: A follow-up analysis was performed on 118 patients with NSCLC resected by lobectomy or pneumectomy with systematic lymph node dissection. All patients were followed for 6-60 months. Immunostaining of tissue sections from primary tumors and their lymph node metastasis was performed and evaluated using monoclonal antibody against MCAM, E-cadherin, and vimentin. Correlations were investigated between MCAM immunostaining in primary tumors and E-cadherin, vimentin immunostaining, lymph node metastasis, and survival. RESULTS:MCAM protein expression was found in 46.61 % of squamous cell carcinomas and 37.47 % of adenocarcinomas; MCAM expression positively correlated with vimentin, but inversely with E-cadherin (both P values <0.05). There were significant correlations between the MCAM immunostaining score in primary tumors and in their lymph node metastasis (P = 0.03). According to the Kaplan-Meier survival estimate, the level of MCAM expression in primary tumors was a statistically significant prognostic factor (P < 0.05). CONCLUSIONS:MCAM expression in surgically treated NSCLC is clearly associated with lymph node metastasis and poor prognosis.
Authors: N Bardin; F Anfosso; J M Massé; E Cramer; F Sabatier; A Le Bivic; J Sampol; F Dignat-George Journal: Blood Date: 2001-12-15 Impact factor: 22.113
Authors: Maya Zigler; Gabriel J Villares; Andrey S Dobroff; Hua Wang; Li Huang; Russell R Braeuer; Takafumi Kamiya; Vladislava O Melnikova; Renduo Song; Ran Friedman; Rhoda M Alani; Menashe Bar-Eli Journal: Cancer Res Date: 2011-04-05 Impact factor: 12.701
Authors: Verena Tischler; Marco Pfeifer; Silke Hausladen; Uwe Schirmer; Anne-Katrine Bonde; Glen Kristiansen; Martin L Sos; Walter Weder; Holger Moch; Peter Altevogt; Alex Soltermann Journal: Mol Cancer Date: 2011-10-10 Impact factor: 27.401
Authors: Gwladys Zabouo; Anne-Marie Imbert; Jocelyne Jacquemier; Pascal Finetti; Thomas Moreau; Benjamin Esterni; Daniel Birnbaum; François Bertucci; Christian Chabannon Journal: Breast Cancer Res Date: 2009-01-05 Impact factor: 6.466
Authors: Reinier Hernandez; Haiyan Sun; Christopher G England; Hector F Valdovinos; Todd E Barnhart; Yunan Yang; Weibo Cai Journal: Mol Pharm Date: 2016-06-10 Impact factor: 4.939
Authors: Joseph W Wragg; Jonathan P Finnity; Jane A Anderson; Henry J M Ferguson; Emilio Porfiri; Rupesh I Bhatt; Paul G Murray; Victoria L Heath; Roy Bicknell Journal: Cancer Res Date: 2016-02-26 Impact factor: 12.701
Authors: Reinier Hernandez; Haiyan Sun; Christopher G England; Hector F Valdovinos; Emily B Ehlerding; Todd E Barnhart; Yunan Yang; Weibo Cai Journal: Theranostics Date: 2016-08-08 Impact factor: 11.556